2-甲基-2-(甲硫基)-丁烷 | 13286-92-5

• 分子结构分类: 有机化合物 - 有机硫化合物 - 硫醚类
• 中文名称: 2-甲基-2-(甲硫基)-丁烷
• 英文名称: 2-methyl-2-(methylthio)butane
• 英文别名: 2-Methyl-2-butyl methylsulfid；tert-Amyl-methylsulfid；Methyl-(1,1-dimethyl-propyl)-sulfid；Methyl-tert.-pentylsulfid；(1,1-Dimethyl-propyl)-methyl-thioether；2-methyl-2-methylsulfanyl-butane；Sulfide, methyl tert-pentyl；2-methyl-2-methylsulfanylbutane
• CAS: 13286-92-5
• 化学式: C₆H₁₄S
• 分子量: 118.243
• InChiKey: SJOHDSPLOVBXOF-UHFFFAOYSA-N

物化性质

• 熔点：
  -96.69°C (estimate)
• 沸点：
  149.85°C
• 密度：
  0.8161
• LogP：
  2.761 (est)
• 保留指数：
  847;847;847

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  7
• 可旋转键数：
  2
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  25.3
• 氢给体数：
  0
• 氢受体数：
  1

安全信息

• 安全说明：
  S23,S24/25
• 危险类别码：
  R10
• 海关编码：
  2930909090

反应信息

• 作为产物：
  描述：

  2-甲基-2-丁硫醇 、 碘甲烷 在 正丁基锂 作用下， 以 四氢呋喃 、 正己烷 为溶剂， 反应 0.5h， 生成 2-甲基-2-(甲硫基)-丁烷
  参考文献：
  名称：

  Structure–Odor Correlations in Homologous Series of Alkanethiols and Attempts To Predict Odor Thresholds by 3D-QSAR Studies

  摘要：

  Homologous series of alkane-1-thiols, alkane-2-thiols, alkane-3-thiols, 2-methylalkane-1-thiols, 2-methylalkane-3-thiols, 2-methylalkane-2-thiols, and alkane-1,?-dithiols were synthesized to study the influence of structural changes on odor qualities and odor thresholds. In particular, the odor thresholds were strongly influenced by steric effects: In all homologous series a minimum was observed for thiols with five to seven carbon atoms, whereas increasing the chain length led to an exponential increase in the odor threshold. Tertiary alkanethiols revealed clearly lower odor thresholds than found for primary or secondary thiols, whereas neither a second mercapto group in the molecule nor an additional methyl substitution lowered the threshold. To investigate the impact of the SH group, odor thresholds and odor qualities of thiols were compared to those of the corresponding alcohols and (methylthio)alkanes. Replacement of the SH group by an OH group as well as S-methylation of the thiols significantly increased the odor thresholds. By using comparative molecular field analysis, a 3D quantitative structureactivity relationship model was created, which was able to simulate the odor thresholds of alkanethiols in good agreement with the experimental results. NMR and mass spectrometric data for 46 sulfur-containing compounds are additionally supplied.

  DOI：

  10.1021/jf506135c

文献信息

• ANTIVIRAL COMPOUNDS
  申请人：Aktoudianakis Evangelos

  公开号：US20100022508A1

  公开（公告）日：2010-01-28

  The invention is related to anti-viral compounds, compositions containing such compounds, and therapeutic methods that include the administration of such compounds, as well as to processes and intermediates useful for preparing such compounds.

  这项发明涉及抗病毒化合物，含有这种化合物的组合物，以及包括给予这种化合物的治疗方法，还涉及用于制备这种化合物的过程和中间体。
• [EN] BENZIMIDAZOLE DERIVATIVES AND USE THEREOF AS PEPTIDE DEFORMYLASE INHIBITORS<br/>[FR] DERIVES DE BENZIMIDAZOLE ET LEUR APPLICATION COMME INHIBITEURS DE LA PEPTIDE-DEFORMYLASE
  申请人：ARPIDA AS

  公开号：WO2005037272A1

  公开（公告）日：2005-04-28

  Benzimidazole compounds of the general formula (I) and pharmaceutically acceptable salts or esters thereof are peptide deformylase inhibitors useful in the treatment or prevention of infections and other diseases in which peptide deformylases are involved, especially in the treatment of bacterial and parasitic infections, for example infections fully or partly caused by microorganisms belonging to Staphylococcus, Enterococcus, Streptococcus, Haemophilus, Moraxella, Escherichia, Mycobacterium, Mycoplasma, Pseudomonas, Chlamydia, Rickettsia, Klebsiella, Shigella, Salmonella, Bordetella, Clostridium, helicobacter, Campylobacter, Legionella, or Neisseria.

  通用公式（I）的苯并咪唑化合物及其药用可接受的盐或酯是肽变形酶抑制剂，在治疗或预防涉及肽变形酶的感染和其他疾病方面具有用处，特别是在治疗细菌和寄生虫感染方面，例如完全或部分由属于葡萄球菌、肠球菌、链球菌、流感嗜血杆菌、嗜莫克菌、大肠杆菌、支原体、支原体、假单胞菌、沙眼衣原体、立克次体、克雷伯菌、志贺菌、沙门氏菌、百白破杆菌、梭菌、幽门螺杆菌、空肠弯曲菌、军团菌或莫拉克细菌引起的感染。
• Antiviral agent
  申请人：——

  公开号：US20040229909A1

  公开（公告）日：2004-11-18

  The present invention provides an integrase inhibitor. The inventors have have found the following compound of formula (I) possessing an integrase inhibitory activity. 1 (wherein, R C and R D taken together with the neighboring carbon atoms form a ring which may be a condensed ring, Y is hydroxy, mercapto or amino; Z is O, S or NH; R A is a group shown by 2 (wherein, C ring is N-containing aromatic heterocycle) or the like)

  本发明提供了一种整合酶抑制剂。发明人发现以下化合物具有整合酶抑制活性，其化学式为(I)。其中，RC和RD与相邻的碳原子一起形成一个环，该环可以是一个缩合环，Y是羟基，巯基或氨基; Z是O，S或NH; RA是由2所示的基团（其中，C环是含N的芳香杂环）或类似基团。
• Heterocyclic compounds having inhibitory activity against hiv integrase
  申请人：Murai Hitoshi

  公开号：US20060128669A1

  公开（公告）日：2006-06-15

  A heterocyclic compound of the formula (I): wherein B 1 is —C(R 2 )═ or —N═; R 1 ′ is H, etc.; one of R 1 and R 2 is -Z 1 -Z 2 -Z 3 -R 5 wherein Z 1 and Z 3 are independently single bond, optionally substituted alkylene, etc.; Z 2 is single bond, optionally substituted alkylene, etc.; R 5 is optionally substituted aryl, optionally substituted heteroaryl, etc., and the other of R 1 and R 2 is H; -A 1 - is —C(—Y)═C(—R A )—C(—R 3 )═C(—R 4 )—, etc. wherein Y is OH, etc.; R A is —COR 7 wherein R 7 is OH, etc.; one of R 3 and R 4 is carboxy, etc., and the other of R 1 and R 2 is H, etc, a prodrug thereof, a pharmaceutically acceptable salt thereof, and a solvate thereof, having an antiviral activity, more particularly, an inhibitory activity against HIV integrase, and a pharmaceutical composition containing the same, especially an anti-HIV drug.

  化合物的公式（I）为杂环化合物，其中B1为—C（R2）═或—N═; R1'为H等; R1和R2中的一个是—Z1-Z2-Z3-R5，其中Z1和Z3分别为单键，可选地取代的烷基等; Z2为单键，可选地取代的烷基等; R5为可选地取代的芳基，可选地取代的杂环芳基等，而R1和R2中的另一个是H; -A1-为—C（—Y）═C（—RA）—C（—R3）═C（—R4）—等，其中Y为OH等; RA为—COR7，其中R7为OH等; R3和R4中的一个是羧基等，而R1和R2中的另一个是H等，其为前药、药学上可接受的盐以及其溶剂化物，具有抗病毒活性，特别是对HIV整合酶的抑制活性，以及含有该化合物的制药组合物，特别是抗HIV药物。
• Heterocyclic compounds having inhibitory activity against HIV integrase
  申请人：Murai Hitoshi

  公开号：US20060247212A1

  公开（公告）日：2006-11-02

  A heterocyclic compound of the formula (I): wherein B 1 is —C(R 2 )═ or —N═; R 1 ′ is H, etc.; one of R 1 and R 2 is -Z 1 -Z 2 -Z 3 -R 5 wherein Z 1 and Z 3 are independently single bond, optionally substituted alkylene, etc.; Z 2 is single bond, optionally substituted alkylene, etc.; R 1 is optionally substituted aryl, optionally substituted heteroaryl, etc., and the other of R 1 and R 2 is H; -A 1 - is —C(—Y)═C(—R A )—C(—R 3 )═C(—R 4 )—, etc. wherein Y is OH, etc.; R A is —COR 7 wherein R 7 is OH, etc.; one of R 3 and R 4 is carboxy, etc., and the other of R 1 and R 2 is H, etc, a prodrug thereof, a pharmaceutically acceptable salt thereof, and a solvate thereof, having an antiviral activity, more particularly, an inhibitory activity against HIV integrase, and a pharmaceutical composition containing the same, especially an anti-HIV drug.

  化合物的式子为(I)的杂环化合物：其中B1为—C(R2)═或—N═；R1'为H等；R1和R2中的一个为-Z1-Z2-Z3-R5，其中Z1和Z3分别为单键，可选地取代的烷基等；Z2为单键，可选地取代的烷基等；R1为可选地取代的芳基，可选地取代的杂环芳基等，而R1和R2中的另一个为H；-A1-为—C(—Y)═C(—RA)—C(—R3)═C(—R4)—等，其中Y为OH等；RA为—COR7，其中R7为OH等；R3和R4中的一个为羧基等，而R1和R2中的另一个为H等。该化合物的前药、药学上可接受的盐和其溶剂化物具有抗病毒活性，特别是对HIV整合酶的抑制活性，以及含有该化合物的药物组合物，尤其是抗HIV药物。

表征谱图